Find trials
Search tips

A Study of Novel Biomarkers in Suspected Cardiogenic Shock

Overview

About this study

The purpose of this study is to assess biomarkers of Cardiogenic Shock (CS) which may be associated with the development of and outcomes after CS to provide incremental prognostic information beyond the standard metrics for hospitalized patients with suspected cardiogenic shock.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Adults admitted to inpatient Cardiology services (Cardiology PCU or CICU) at Mayo Clinic Saint Marys Hospital
  • Enrolled in Epic Cardiogenic Shock Care Path (triggered automatically by admission order to any Cardiology inpatient hospital service)
  • Suspected or confirmed cardiogenic shock, defined as triggering Epic Cardiogenic Shock Care Path alert criteria for SCAI Shock Stage C, D, or E for the first time

Exclusion Criteria:

  • Comfort cares
  • Goals of care do not include ICU admission
  • Vulnerable or protected populations
  • Inability to collect and/or process initial blood sample for biomarker analysis within protocol required timeframe (collected within 6 hours of initial SCAI Shock Stage C, D, or E alert and processed & stored within 4 hours of sample collection)
  • Participant and/or LAR unable or unwilling to provide written informed consent.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 02/25/2025. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jacob Jentzer, M.D.

Contact us for the latest status

Contact information:

Matthew Adolphsen

(507) 422-5919

Adolphsen.Matthew@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20582787

Mayo Clinic Footer